Implantation of Anterior Segment Intraocular Nonbiodegradable Drug-Eluting System
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage for implantation of anterior segment intraocular non-biodegradable drug-eluting systems (e.g., intracameral travoprost implant) for treatment of open-angle glaucoma or ocular hypertension for BCBSRI Medicare Advantage and Commercial products.
No material clinical or coverage changes in this revision.
Coverage Criteria
Coverage statement
Covered when the following product/population applies.
No additional medical necessity criteria provided in this document.
Coverage for implantation of an anterior segment intraocular non-biodegradable drug-eluting system (for example, an intracameral travoprost implant) is provided for Medicare Advantage Plans and Commercial Products when the member’s benefits allow such services. No additional medical necessity criteria are specified in this policy document; determine applicability based on the member’s plan benefits and any applicable participation agreements.
Members and providers should note that while the procedure and associated codes (e.g., implantation and device supply) are addressed in this policy, actual benefit determination is subject to the member’s certificate of coverage. Refer to member documents for final coverage determination.
Benefits may vary between groups and contracts. Always consult the member’s Benefit Booklet, Evidence of Coverage (EOC), or Subscriber Agreement to confirm whether implantation of an anterior segment intracameral drug-eluting implant is a covered service for that member. Lack of an applicable benefit in those documents could result in a denial of payment.
Coding and Regulatory
Provider Actions and Requirements
Provider operational notice: verify benefits and contractual obligations
Verify member benefits and eligibility via the provider call center before scheduling; follow provider participation agreements for billing and member financial responsibility.
- Contact the provider call center for member‑specific benefits and eligibility information.
- Adhere to provisions in your participation agreement regarding member billing and collections.
Member eligibility and consent required
Confirm member eligibility and obtain documented member consent if proceeding with services that may be non‑covered or not medically necessary under the member's benefit documents.
- Verify benefits and eligibility using the provider call center.
- Obtain written member agreement/consent before providing services that the member may be financially responsible for.
- Refer to the member's subscriber agreement, member certificate, or employer agreement for benefit determinations.
Benefit/coverage mismatch — verify member booklet/EOC/subscriber agreement
Benefits may vary between groups/contracts; if the member’s Benefit Booklet, Evidence of Coverage, or Subscriber Agreement does not include an applicable benefit, the service may be denied.
- Refer to the Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable covered/not‑covered benefits.
- A lack of an applicable benefit in those documents could trigger a denial.
Background
Drug-eluting anterior segment intracameral implants were developed to address poor adherence to topical glaucoma medications by providing sustained intraocular delivery of a therapeutic agent (for example, travoprost). These implants are anchored through the trabecular meshwork into the sclera and elute drug over an extended period to lower intraocular pressure, potentially improving adherence and maintaining therapeutic effect without reliance on daily topical drops. The manufacturer Glaukos’ iDose TR® is an example of an FDA-approved sustained-release intracameral travoprost implant (FDA approval reported Dec 13, 2023).
Because this technology provides continuous drug delivery from an implanted device rather than intermittent patient-administered eye drops, the rationale for coverage centers on improved medication adherence and sustained intraocular pressure control for appropriate patients with open-angle glaucoma or ocular hypertension; however, final coverage depends on the member’s plan benefits.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.